The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

ClinicalTrials.gov ID: NCT00899678

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00899678. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of certolizumab pegol treatment in pediatric subjects, aged 6 to 17, with moderately to severely active Crohn's disease. The target enrollment is 160 subjects.

Study identification

NCT ID: NCT00899678
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: UCB Celltech; Industry
Enrollment: 99 participants

Conditions and interventions

Conditions

Crohn's Disease

Interventions

Certolizumab Pegol Drug

Drug

Eligibility (public fields only)

Age range: 6 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2009 (Type not available)
Primary completion: Jul 2012 (Actual)
Completion: Jul 2012 (Actual)
Last update posted: Aug 7, 2018

2009 – 2012

United States locations

U.S. sites: 24
U.S. states: 21
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	—	—
Not listed	Los Angeles	California	—	—
Not listed	Orange	California	—	—
Not listed	San Francisco	California	—	—
Not listed	Aurora	Colorado	—	—
Not listed	Hartford	Connecticut	—	—
Not listed	Orlando	Florida	—	—
Not listed	Atlanta	Georgia	—	—
Not listed	Chicago	Illinois	—	—
Not listed	Indianapolis	Indiana	—	—
Not listed	Lexington	Kentucky	—	—
Not listed	Shreveport	Louisiana	—	—
Not listed	Baltimore	Maryland	—	—
Not listed	Boston	Massachusetts	—	—
Not listed	Rochester	Minnesota	—	—
Not listed	Morristown	New Jersey	—	—
Not listed	New Hyde Park	New York	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Nashville	Tennessee	—	—
Not listed	Dallas	Texas	—	—
Not listed	Houston	Texas	—	—
Not listed	Seattle	Washington	—	—
Not listed	Milwaukee	Wisconsin	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00899678, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 7, 2018 · Synced Nov 14, 2026